Related Experiment Video
Updated: Oct 2, 2026

Glutamine Flux Imaging Using Genetically Encoded Sensors
Published on: July 31, 2014
Molecular characterisation of glutamate dehydrogenase gene defects in Japanese patients with congenital
1Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan.
Insights
Congenital hyperinsulinism and hyperammonaemia (CHH) results from glutamate dehydrogenase (GDH) gene mutations. Specific mutations L413V and G446D cause varying enzyme dysfunction, correlating with CHH patient phenotypes.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Congenital hyperinsulinism and hyperammonaemia (CHH) is a metabolic disorder linked to glutamate dehydrogenase (GDH) dysregulation.
- GDH enzyme activity is modulated by GTP and ADP, crucial for regulating ammonia and glucose metabolism.
Purpose of the Study:
- To characterize GDH gene mutations in two Japanese patients with CHH.
- To correlate specific GDH mutations with biochemical and clinical phenotypes.
Main Methods:
- Genetic analysis of the GDH gene in patients and their families.
- Measurement of GDH enzyme activity and allosteric regulation in lymphoblasts.
- COS cell expression studies to confirm pathogenicity of identified mutations.
Main Results:
- Identified heterozygous, de novo GDH mutations L413V in patient 1 and G446D in patient 2.
- Patient 1 (L413V) exhibited mild insensitivity to GTP inhibition and higher basal GDH activity, correlating with milder symptoms.
- Patient 2 (G446D) showed severe GTP insensitivity, with mutations located in critical functional sites of the GDH enzyme.
Conclusions:
- The identified GDH mutations L413V and G446D are disease-causing in CHH.
- Mutation location and biochemical effects explain the varying clinical severity observed in the patients.
- The antenna-like structure of GDH is critical for enzyme activity and is impacted by these mutations.
Abstract:
Congenital hyperinsulinism and hyperammonaemia (CHH) is caused by dysregulation of glutamate dehydrogenase (GDH). We characterised the GDH gene in two Japanese patients with CHH. Patient 1 showed late-onset and mild hypoglycaemic episodes and mild hyperammonaemia, compared with patient 2. In GDH activity of lymphoblasts, patient 1 showed twofold higher basal GDH activity than control subjects and mild insensitivity for GTP inhibition. Patient 2 showed severe insensitivity for GTP inhibition, and similar allosteric stimulation by ADP in the controls. Genetic studies identified heterozygous and de novo L413V and G446D mutations in patients 1 and 2, respectively. COS cell expression study confirmed that both mutations were disease-causing gene. The insensitivity for GTP inhibition in L413V and G446D was emphasised in COS cell expression system as a result of the dosage effect of mutant GDH gene. L413V showed less impairment of GDH than G446D based on biochemical and genetic results, which was consistent with the clinical phenotype. Based on the structure of bovine GDH, G446D was located in GTP binding site of pivot helix and its surroundings, while L413V was located in alpha-helix of antenna-like structure. These different locations of mutations gave different effects on GDH enzyme. The antenna-like structure plays an important role in GDH activity.
Related Concept Videos
Inborn Errors of Metabolism
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Lysosomal Hydrolases

